Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Merlo

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Neuro-Oncology|March 11, 2010
Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I studyDominik Cordier, Flavio Forrer, Stefan Kneifel, et al.
Cancer|January 11, 2005
Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapyDaniel Beutler, Pierino Avoledo, Jean-Claude Reubi, et al.
Clinical Nuclear Medicine|February 28, 2023
Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence ParametersLeszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, et al.
BMC Neurology|May 28, 2010
Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhageChristian Zweifel, Mira Katan, Philipp Schuetz, et al.
Neuro-Oncology|July 24, 2013
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δAlexander Schulte, Katrin Liffers, Annegret Kathagen, et al.
Cancer Research|March 17, 2011
MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastomaMichal Grzmil, Pier Morin, Maria Maddalena Lino, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2021
Dose escalation study of targeted alpha therapy with [<sup>225</sup>Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacyLeszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, et al.
International Journal of Molecular Sciences|November 14, 2023
Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?Leszek Krolicki, Jolanta Kunikowska, Dominik Cordier, et al.
Plos One|October 14, 2009
GSK3beta regulates differentiation and growth arrest in glioblastomaSerdar Korur, Roland M Huber, Balasubramanian Sivasankaran, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 1, 2007
Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomasStefan Kneifel, Peter Bernhardt, Helena Uusijärvi, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Neuro-Oncology|March 11, 2010
Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I studyDominik Cordier, Flavio Forrer, Stefan Kneifel, et al.
Cancer|January 11, 2005
Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapyDaniel Beutler, Pierino Avoledo, Jean-Claude Reubi, et al.
Clinical Nuclear Medicine|February 28, 2023
Locoregional Treatment of Glioblastoma With Targeted α Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence ParametersLeszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, et al.
BMC Neurology|May 28, 2010
Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhageChristian Zweifel, Mira Katan, Philipp Schuetz, et al.
Neuro-Oncology|July 24, 2013
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δAlexander Schulte, Katrin Liffers, Annegret Kathagen, et al.
Cancer Research|March 17, 2011
MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastomaMichal Grzmil, Pier Morin, Maria Maddalena Lino, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2021
Dose escalation study of targeted alpha therapy with [<sup>225</sup>Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacyLeszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska, et al.
International Journal of Molecular Sciences|November 14, 2023
Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?Leszek Krolicki, Jolanta Kunikowska, Dominik Cordier, et al.
Plos One|October 14, 2009
GSK3beta regulates differentiation and growth arrest in glioblastomaSerdar Korur, Roland M Huber, Balasubramanian Sivasankaran, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 1, 2007
Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomasStefan Kneifel, Peter Bernhardt, Helena Uusijärvi, et al.
Pageof 5